|
发表于 2018-1-10 23:00:07
|
显示全部楼层
来自: 中国陕西西安
MEDLINE®
Targeting malignancies with disulfiram (Antabuse): multidrug resistance, angiogenesis, and proteasome.
Abstract
An old drug, Antabuse (disulfiram), used for decades in alcohol aversion therapy, and its metabolite Ditiocarb were shown from 1970s to suppress cancer growth in vivo and even in human patients. The drug targets multidrug resistance, angiogenesis, invasion, and proteasome. Today, there are ongoing clinical trials of Antabuse as an adjuvant therapy against lung cancer and as a monotherapy against cancers metastasizing to liver. The larger clinical trials, if appropriate, will need support from governments and charities to get the generic drug into the clinic as a "non-profit" drug.
Citation
Targeting malignancies with disulfiram (Antabuse): multidrug resistance, angiogenesis, and proteasome.
Cvek B - Curr Cancer Drug Targets - March 1, 2011; 11 (3); 332-7
MEDLINE is the source for the citation and abstract for this record
Full Source Title
Current cancer drug targets
NLM Citation ID
21247389 (PubMed ID)
Language
eng
Author Affiliation
Authors
Cvek B
MeSH Terms (9)
Clinical Trials as Topic
Disulfiram /therapeutic use *
Drug Resistance, Multiple *
Drug Resistance, Neoplasm
Humans
Neoplasms /drug therapy * /metabolism
Neovascularization, Pathologic /drug therapy *
Protease Inhibitors /therapeutic use *
Proteasome Inhibitors *
麻烦楼主找一下这篇文章 我找到的只有摘要,没有正文 |
|